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Abstract: The Plasticity Related Gene family covers five, brain-specific, transmembrane proteins (PRG1-
5, also termed LPPR1-5) that operate in neuronal plasticity during development, aging and brain trauma.
Here we investigated the role of the PRG family on axonal and filopodia outgrowth. Comparative analysis
revealed the strongest outgrowth induced by PRG3 (LPPR1). During development, PRG3 is ubiquitously
located at the tip of neuronal processes and at the plasma membrane and declines with age. In utero elec-
troporation of PRG3 induced dendritic protrusions and accelerated spine formations in cortical pyramidal
neurons. The neurite growth promoting activity of PRG3 requires RasGRF1 (RasGEF1/Cdc25) medi-
ated downstream signaling. Moreover, in axon collapse assays, PRG3-induced neurites resisted growth
inhibitors such as myelin, Nogo-A (Reticulon/RTN-4), thrombin and LPA and impeded the RhoA-Rock-
PIP5K induced neurite repulsion. Transgenic adult mice with constitutive PRG3 expression displayed
strong axonal sprouting distal to a spinal cord lesion. Moreover, fostered PRG3 expression promoted
complex motor-behavioral recovery compared to wild type controls as revealed in the Schnell swim test
(SST). Thus, PRG3 emerges as a developmental RasGRF1-dependent conductor of filopodia formation
and axonal growth enhancer. PRG3-induced neurites resist brain injury-associated outgrowth inhibitors
and contribute to functional recovery after spinal cord lesions. Here, we provide evidence that PRG3
operates as an essential neuronal growth promoter in the nervous system. Maintaining PRG3 expression
in aging brain may turn back the developmental clock for neuronal regeneration and plasticity.
DOI: 10.18632/aging.101066
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Neuronal plasticity and structural remodelling are 
fundamental feature of the developing nervous system 
and plays also an essential role during learning and 
injury-dependent remodelling and regeneration [1]. In 
development, axons extend over long distances and 
form contacts with their target structure and facilitate 

























The Plasticity Related Gene  family  covers  five, brain‐specific,  transmembrane proteins  (PRG1‐5, also  termed 
LPPR1‐5) that operate in neuronal plasticity during development, aging and brain trauma. Here we investigated 
the  role of  the PRG  family on  axonal and  filopodia outgrowth. Comparative analysis  revealed  the  strongest 
outgrowth induced by PRG3 (LPPR1). During development, PRG3 is ubiquitously located at the tip of neuronal 
processes  and  at  the  plasma  membrane  and  declines  with  age.  In  utero  electroporation  of  PRG3  induced 




constitutive  PRG3  expression  displayed  strong  axonal  sprouting  distal  to  a  spinal  cord  lesion.  Moreover, 
fostered  PRG3  expression  promoted  complex motor‐behavioral  recovery  compared  to wild  type  controls  as 
revealed in the Schnell swim test (SST). Thus, PRG3 emerges as a developmental RasGRF1‐dependent conductor 
of  filopodia  formation  and  axonal  growth  enhancer.  PRG3‐induced  neurites  resist  brain  injury‐associated 
outgrowth inhibitors and contribute to functional recovery after spinal cord lesions. Here, we provide evidence 
that  PRG3  operates  as  an  essential  neuronal  growth  promoter  in  the  nervous  system.  Maintaining  PRG3 
expression in aging brain may turn back the developmental clock for neuronal regeneration and plasticity. 
Research Paper 
www.aging‐us.com  2464  AGING (Albany NY) 
functional connections [2]. These neuronal connections 
become stabilized and restricted during maturation and 
secure proper functioning of the brain [1]. Conversely, 
sprouting and regeneration is limited after decline of 
intrinsic axonal remodelling activity in aging brain and 
in an microenvironment rich in neurite growth 
inhibitors after neurological injury [3].  
 
Several extracellular ligands account for the neurite 
growth inhibitory environment after maturation and 
injury [3]. One such factor represents lysophosphatidic 
acid (LPA) which is a bioactive lipid borne from 
astrocytes and blood serum [4-6]. Another blood 
inherent factor with neural shape forming activity is 
thrombin and its receptor-activating peptide domain 
(TRP). Nogo-A/RTN4 (Reticulon-4) is a myelin-
associated inhibitor derived from oligodendrocytes 
found to execute neurite growth inhibitory and 
collapsing activity in the adult [7, 8]. Although LPA, 
TRP and Nogo-A act on different receptors (LPA on 
LPA1-5 receptors; TRP on thrombin receptor and 
Nogo-A on NgR and PirB/LILRB2), all ligands 
converge on RhoA -Rho kinase pathway mediating the 
final signal transduction for neurite retraction and axon 
growth inhibition [9]. Concomitantly, recent landmark 
studies revealed that pharmacological and genetic 
interfering with Nogo/NgR function or LPA signaling 
promotes axonal regeneration and functional recovery 
after CNS injury [10, 11]. 
 
An essential step during development and regeneration 
is the initiation of actin-rich membrane protrusions 
termed filopodia or microspikes. These structures are 
involved in cell attachment, migration and neurite 
growth [12]. Filopodia initiation and neural growth 
depends on cytoskeletal dynamics regulated to a large 
extent by the small molecular weight GTPases of the 
Rho family. In particular, the Rho family GTPase 
Cdc42 regulates bundled actin filaments extending from 
the cell periphery, forming canonical filopodia of 
different length and width [13]. Historically, filopodia 
initiation research focused around the activation of 
WASP and N-WASP by Cdc42 [14]. The interaction of 
Cdc42 with WASP and N-WASP in the presence of 
phosphatidylinositol-4,5-bisphosphate (PIP2) leads to 
activation of the ARP2/3 complex which acts as a 
nucleator and growth promoter for actin filaments. 
However, Cdc42-independent filopodia formation also 
exists. However, WASP and N-WASP is often not 
present in filopodia and neurite growth occurs even in 
the absence of N-WASP [15, 16]. Moreover, depletion 
of upstream Cdc42 or downstream ARP2/3 leaves 
filopodia growth unaffected [17, 18]. The recently 
discovered formins, known as actin regulatory proteins 
located at the tips of filopodia indicates an alternative 
growth pathway [19, 20]. Formins act independently of 
ARP2/3 and recruit the GTPase Rif (Rho in filopodia) 
instead of Cdc42. These molecules are critically 
involved in neurite growth control and are implicated to 
overcome neurite growth inhibition signals [21]. 
Interestingly, PRG3 acts independently of Cdc42 and 
VASP family proteins, pointing to a recently discovered 
role of integral membrane proteins in the shaping of 
membrane curves [22].  
 
Here, we describe the individual morphogenic activity 
of the integral membrane proteins Plasticity Related 
Genes also termed Lipid Phosphate Phosphatases 
Related genes (PRG 1-5 or LPPR 1-5). They are 
differentially expressed in the developing brain and re-
expressed in regenerating axons after a lesion [11, 23]. 
In particular, PRG3 induces the formation of filopodia 
and promotes axonal growth [23]. The sequence of 
PRG3 is highly related to PRG5 which also promotes 
morphological changes in neurons [24]. However, our 
comparative analysis revealed a hierarchy with PRG3 
displaying the strongest outgrowth promoting activity 
among the entire PRG family. 
 
We characterized the required PRG3 domains for 
filopodia inducing activity and found that the 
localization of the carboxyl terminal is critical for 
neurite growth. Moreover, PRG3 overcomes neurite 
retraction of common brain and blood borne neurite 
growth inhibitors such as Thrombin, Nogo-A and LPA 




PRG family members change neuronal cell shape 
differently 
 
We described previously that a subtraction hybridization 
screen and degenerative PCR primer search led to the 
identification of the Plasticity Related Gene family 
(PRG) (Fig. 1 A) [11, 23, 24]. Sequence alignments of all 
five PRG members revealed high homology in all six 
transmembrane domains. However, the carboxy terminus 
(CT) located domain varies significantly among the PRG 
members with high sequence similarity between PRG3 
and PRG5 (Fig. S 1). Human PRG3 amino acid sequence 
shares 57 % homology to PRG5 indicating it as its closest 
relative within the PRG family. Structural searches 
predict three extracellular domains D1-D3, also 
conserved in a subset of the type 2 phosphatidic acid 
phosphatase ectoenzyme superfamily (prototypic lipid 
phosphate phosphatase 1 and 3, (LPP1, LPP3)) (Fig. S 1). 
The five PRG family members identified in the human 
genome differ in tissue distribution and expression (Fig. 1 
B). The expression of individual PRGs varies particularly 
in cerebral cortex, olfactory bulb, and nucleus accumbens 
among each other (Fig. 1 B).  





















































































































right)  in  the mouse. Note,  that expression of PRGs  is preferably high  in different brain areas  (black  framed box). PRG1  is expressed
highest with an average of 472.1 and PRG2 is lowest with 10.1 in average (average compared to overall mean expression of individual
array). Notably, PRG2  is also expressed  in myeloid progenitors  (black arrowheads).  (C) Comparative analysis of GFP and various PRG
family members  in  (GFP  and PRG1  to 5‐GFP,  left  to  right)  in murine neuronal  cells N1E‐115. Overexpression of PRG3  and PRG5  in
particular enhanced filopodia formation and neurite outgrowth (white arrowheads). Expression of PRG1 and PRG2 do not challenge the
neuronal phenotype compared to controls. PRG4 induces a bipolar phenotype (arrowheads). Scale bar represents 20 µm.  
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We analysed the distribution of the PRG family 
members and their impact on neuronal cell morphology. 
PRG proteins were localised at the plasma membrane of 
neuronal cells, but only PRG3 and PRG5 displayed 
enriched distribution at the tips of neurites and 
microspikes (Fig. 1 C). Moreover, solely PRG3 and to a 
lesser extent PRG5 caused massive neurite and 
filopodia growth (Fig. 1 C). On the other hand, PRG4 
induced a bipolar spindle-like phenotype and PRG1 and 
PRG2 marginally altered cellular morphology compared 
to GFP expressing control cells (Fig. 1 C). 
 
We performed automated cell phenotype analysis with a 
modified version of the publicly available neuronal 
outgrowth pipeline (CellProfiler 2.0, Broad Institute 
Harvard/MIT). Three parameters covering neuronal tree 
complexity were analysed:  
1. number of trunk branches, indicating branches 
directly connected to the cell body (soma);  
2. number of branch ends, labelling branch tips and  
3. number of non-trunk branches, peripheral neurite 
connections neither directly connected to the soma nor 
to branch ends.  
First, we identified a significant increase of trunk-
associated neurites in PRG3-expressing neurons which 
was strongest compared to other PRG family members 
(Fig. S 1 B). Second, the number of secondary and 
tertiary branches was also significantly increased. 
Finally, PRG3 expression multiplied the number of 
branch ends compared to controls (Fig. S1 C).  
 
In vivo neuronal morphology shape by PRG3 
 
We further investigated PRG3 location ex vivo and 
found it expressed in axon tips of primary neurons (Fig. 
2 A). Endogenous PRG3 was located at the tip of actin-
rich growth cones of cortical neurons (Fig. 2 A; Fig. S 
2). Interestingly, primary astrocytes were almost 
immuno-negative for PRG3 (Fig. S 2). To investigate 
whether PRG3 has a general impact on neuronal 
morphology independently of the type of neurons, we 
studied this gene in cerebellar neurons. PRG3 
expression in rat granule neurons caused extensive 
formation of neurites and filopodia in comparison to 
GFP expressing control granule neurons (Fig. 2 B, C). 
Electron microscopy studies of hippocampal synapses 
revealed post-synaptic (Fig. 2 D-G) and occasional pre-
synaptic location of PRG3 (Fig. 2 H-K). Immuno-
histochemistry of brain cryo-sections identified 
hippocampal neurons with high PRG3 levels in the 
adult mouse brain (Fig. 2 N).  
 
For in vivo assessments we performed in utero 
electroporation of mouse embryonic cortical neurons at 
embryonic day 13 (Fig. 2 O) with GFP control and 
PRG3 constructs (Fig. 2 P). Noteworthy, neonates 
survived the procedure without obvious constraints and 
were sacrificed at postnatal day 10 (P10). In depth 
morphometric investigations of single pyramidal neurons 
displayed a higher protrusion density of PRG3 positive 
neurons. These data demonstrate that PRG3 operates on 
neural shape and filopodia in vivo (Fig. 2 P). 
 
PRG3 C-terminal domain promotes neurite growth 
and branching 
 
PRG3 and PRG5 are both the smallest PRG family 
members with the shortest intracellular c-terminal (CT) 
domains of 46 and 47 amino acids, respectively (Fig. S 
1 A). We hypothesized, that the unique CT domain of 
PRG3 which is absent in other PRG family members, 
might be causal for the enhanced differentiated neuronal 
phenotype.  
 
To investigate this further, we generated a PRG3 
construct lacking the CT domain (PRG3ΔCT) and 
another mutant construct with solely the CT domain 
(PRG3CT). Both constructs eliminated the effect 
induced by wild-type PRG3 (Fig. 3 A). We found the 
overexpressed CT domain primarily in the cytosol, 
whereas in the wild-type situation the CT domain is 
located at the plasma membrane. Hence, we fused the 
myristoylation consensus sequence of the YES-kinase 
together with the PRG3CT sequence to generate a 
membrane-targeted PRG3CT fusion protein 
(PRG3CTMEM, Fig. 3 C). The PRG3 phenotype was 
recovered when PRG3CTMEM was expressed with 
respect to number of trunk branches, non-trunk 
branches and branch ends (Fig. 3 D, E). Neurite length 
measurements of GFP, PRG3CTMEM and PRG3 
revealed PRG3CTMEM neurites grew significant longer 
compared to PRG3CT mutants and controls (Fig. 3 D, 
E). Thus, the subcellular localization and final position 
of PRG3CT is significantly linked to the functional 
neurite and filopodia growth promotion activity.  
 
Serving as a control we cloned a YES-GFP construct 
(GFPMEM) to monitor the influence of YES-kinase 
domain on cellular morphology (Fig. 3 D). In fact, 
GFPMEM neuronal shape and neurite processes were 
comparable to wild-type GFP controls (Fig. 3 D).  
 
Furthermore, we tested different domains of PRG3 in 
terms of neurite promoting activity. PRG3CTMEM enhan-
ced neurite length similar to the level of the PRG3 wild-
type (Fig. 3 F). The impact of PRG3 and its CT domain 
on cell morphology was more generally assessed in HeLa 
and embryonic epithelial P19 cells. HeLa cells displayed 
a minor although significantly increased number of trunk 
branches, non-trunk branches and branch ends in the case 
of PRG3 expression (Fig. S3 C-D). No significant 
increase   was   found   after  expression  of  PRG3CTMEM  





















































































































Subcellular analysis reveals post‐synaptic distribution of PRG3. DAB accumulated  in  the cytoplasm  (D). Dendritic spine structures were
also  found  positive  for  PRG3  and  are  indicated  by  asterisks  (E‐G).  Scales:  0.5  µm.  (H‐K) Occasionally,  axonal  boutons  (pre‐synaptic
structures), appeared labeled with PRG3 antibodies (asterisk). Accumulations of DAB appeared especially in the pre‐terminal parts of the
axonal  boutons.  Postsynaptic  elements  are  marked  with  arrows  and  a  labeled  spine  with  an  arrowhead  in  J.  Scales:  0.5  µm.  (N)
Immunohistochemical staining identifies endogenous PRG3 expression (green) is located primarily in the hippocampus in the adult mouse
brain  (Red = TuJ1).  (O) Scheme of  the experimental protocol  for  cortical  in utero electroporation  [55].  (P) Representative example of
electroporated  brain  section  showing  pyramidal  neurons  positive  for  GFP  expressing  pyramidal  neurons  (left)  and  PRG3‐positive
pyramidal  cells  (right).  Neuronal  morphology  was  analysed  at  postnatal  day  10  (P10).  Scale  bar  represents  20  µm.  High‐power
magnifications  of  boxed  areas  show  spines  and  spine‐like  membrane  protrusions,  which  are  indicated  by  arrowheads.  Scale  bar
represents 20 µm. (Q) Number of protrusions per µm dendrite were quantified in 70 µm confocal stacks. Neurons electoroporated with
PRG3  show  significantly more protrusions per µm compared  to GFP electroporated neurons. Values are given as mean ± SEM.  (N=5).
Statistical analysis was performed using two tailed student’s t‐test. P value was set as * = p<0.05: ** = p<0.01; *** = p<0.001. 
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(Fig. S3 C-D). Endogenous PRG3 mRNA was almost 
absent in undifferentiated P19 cells (Fig. S4 B). 
Noteworthy, retinoic acid differentiated P19 cells formed 




















































PRG3 mRNA levels (Fig. S4 B). PRG3 transfection of 
undifferentiated P19 cells significantly increased neurite-
like extensions and filopodia growth (Fig. S3 A-B). No 





















































Figure  3.  Plasma  membrane  localization  of  the  PRG3  C‐terminal  domain  is  essential  for  axon  outgrowth.  (A)  PRG3
overexpression induces neurite outgrowth (PRG3, arrows) in comparison to controls (GFP). A truncated PRG3 construct of its C‐terminal
domain (PRG3ΔCT) and a truncated PRG3 construct consisting of solely the C‐terminus (PRG3CT) was compared. Expression of PRG3ΔCT






























































































































left). siRNA mediated knockdown of RasGRF1  in PRG3 overexpressing cells  (PRG3/siRasGRF1) show  reduced sprouting and
membrane  protrusions  (arrow,  right).  Bottom  panel,  siRNA mediated  knockdown  of  RasGRF1  (right)  does  not  affect  the
morphology of controls (scrambled siRNA‐transfected cells, left, arrows). Scale bar gives 20 µm. (B) Quantification of neurite




shRNA  (siControl) and  two different RasGRF1 RFP‐shRNA knockdown vectors  (siRasGRF #1 and siRasGRF #2)  in PRG3CTMEM
expressing neurons show reduced filopodia formation and neurite outgrowth (arrowheads). Scale bar represents 20 µm. (D)
Quantification of neuronal morphology  in PRG3CTMEM expressing and  siRNA mediated RasGRF1 knockdown  cells. Neurons
were  analysed  for  number  of  branches  at  the  soma  (trunk  branches),  peripheral  branches  (non‐trunk  branches),  and  tip
structures (branch ends). Differences were considered statistically significant with * p<0.05, ** p<0.01, *** p<0.001 (one way
anova, Bonferroni post hoc analysis for multiple comparisons). Values are given as mean ± SEM. 
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PRG3 requires RasGRF1 for axonal outgrowth and 
filopodia induction 
 
We identified potential PRG3 binding candidates in a 
yeast two-hybrid screen using the C-terminal tail of 
PRG3 as bait. Thereby, RasGRF1 (also termed GRF1/ 
RasGEF1/ CDC25) was discovered as a potential 
binding partner of PRG3. Follow-up binding studies 
revealed that PRG3 interacts with RasGRF1 [25]. To 
further proof the functional validity of this interaction, 
we introduced functional RasGRF1 siRNAs (Fig. S4 
A). Reduction of RasGRF1 in PRG3 overexpressing 
clones significantly impaired the neurite and filopodia 
outgrowth phenotype found with PRG3 alone (Fig. 4 A, 
B). Moreover, RasGRF1 silencing resulted in 
neutralizing effects of PRG3CTMEM in neurons (Fig. 4 
D). Trunk branches and branch ends were reduced to 
control levels in PRG3CTMEM neurons when RasGRF1 
was depleted (Fig. 4 D). These data indicate that 
PRG3CT requires RasGRF1 to operate on filopodia and 
neurite growth. 
 
PRG3 modulates RhoA-Rock-PIP5K induced 
signaling 
 
Most myelin-derived neurite growth inhibitors execute 
their effects directly or indirectly through the RhoA-
Rho-PIP5K pathway [26]. RhoA activates its 
downstream target PIP5K, which operates on cyto-
skeleton reorganization [27, 28]. Interestingly, PRG3 
rescued the round phenotype induced by PIP5K, 
without affecting PIP5K expression levels (Fig. 5 A, B). 
This indicates that PRG3 can counteract the neurite 
growth inhibitory action of PIP5K rendering it as a 
potential target for therapeutic interventions. We 
challenged the experiment with the dominant active 
PIP5K upstream effector RhoAV14. RhoAV14 induced 
neurite collapse in control neurons as described 
previously [24]. Co- expression of PRG3 and RhoAV14 
still revealed neurite growth and filopodia formation 
although neurite length was reduced (Fig. 5 C). Further 
upstream, plasma membrane bound PIP2 regulates 
activation of RhoA and PIP5K [29, 30]. Therefore, we 
analyzed PIP2 distribution after PRG3 overexpression. 
These assays revealed that the ratio cytosolic fraction 
vs. membrane bound PIP2 was altered after PRG3 
expression (Fig. 5 D). Conclusively, PRG3 over-
expressing neurons resist neurite retraction by 
modulating RhoA activity via PIP2 membrane 
translocation. 
 
PRG3 neutralizes myelin-growth inhibition 
 
The potential of PRG3 to overcome RhoA induced 
neuronal collapse led us to assess the functional 
implications of PRG3 expression in neurons. We 
determined neuronal spreading activity on myelin 
substrates, a major neurite growth inhibitory substrate 
present in spinal cord injured tissue [7, 8]. 16 hours post 
seeding, control neurons showed almost no neurite 
growth on myelin-substrates (Fig. 5 E). Conversely, 
PRG3 expressing neurons developed neurites in the 
presence of myelin (Fig. 5 E). One critical protein 
causing neuronal retraction inherent in myelin is Nogo-
A/RTN4 [31]. We used the Nogo-A/RTN4-specific, 
axon collapse inducing protein sequence in the 
spreading assay (Δ20 peptide consists of aa position 
544-725 in rat Nogo-A) [31, 32]. Neuronal cells were 
cultured in the presence of different Δ20 concentrations 
to determine whether Nogo-A/RTN4 can exert axonal 
retraction in the presence of PRG3. Concentrations of 
3.2 µM of Δ20 reduced spontaneous outgrowth in 
control cells (Fig. 5 F, G). The Δ21 protein of similar 
molecular weight (aa 812-918 of rat Nogo-A), lacking 
the neurite growth inhibition activity was used as 
negative control (Fig. 5 F, G) [31]. PRG3 neurons 
spread on Δ20 substrate and formed filopodia and 
neurites comparable to Δ21 control substrate (Fig. 5 F, 
H). Interestingly, PRG3CTMEM showed slightly longer 
neurites on Δ21 substrate compared to wild-type PRG3 
expressing cells (Fig. 5 F, H). In contrast, Δ20 
significantly reduced neurite length of PRG3CTMEM 
neurons, where PRG3 full length expressing neurons 
were unaffected (Fig. 5 F, H). These findings suggest 
two separate functional domains for PRG3 with neurite 
growth promoting activity at the CT and a neutralizing 
activity for neurite growth inhibitors.  
 
We continued to investigate the neutralizing neurite 
growth inhibitory activity of PRG3 in time-lapse collapse 
assays. First, we investigated the potent, blood borne 
neurite growth inhibitor lysophosphatidic acid (LPA), 
which acts directly on RhoA via LPA Receptor 
(Kranenburg et al., 1999). Control and PRG3 expressing 
neurons were treated with 500 nM LPA. Approximately 
90 % of all neurites initially displayed collapse in control 
neurons, whereas PRG3 expressing neurons retracted to 
48% of their initial neurite length on average (Fig. 6 A, 
B). This effect could be induced via lipid phosphatase 
activity shown in PRG1 [33]. However, previous 
investigations revealed that PRG3 lacks detectable lipid 
phosphatase activity [22, 23]. Therefore, non-
hydrolysable, phosphatase-resistant LPA (nhLPA) was 
used to verify these reports. The identical collapse assays 
were performed with nhLPA. Again, only control 
neurons contracted after 7.5 min comparable to native 
LPA controls, whereas PRG3 neurites also resisted 
nhLPA-induced neurite collapse (Fig. 7 A, B). General 
LPA receptor expression was unchanged after PRG3 
expression (Fig. S5 C). Thrombin (TRP) represents 
another relevant blood borne neurite growth inhibitor. 
We treated controls and PRG3 expressing  neurons  with 



















































































































Representative  images of neurons expressing GFP and PIP5K  (control) or PRG3 and PIP5K  (PRG3). PRG3‐expressing neurons still retain
their  complex morphology  in  the presence of PIP5K overexpression  (arrows).  Scale bar  represents 20 µm.  (B)  Immunoblot  for PIP5K
expression in PRG3 expressing neurons. Bottom, Actin serves as a house keeping protein for equal gel loading. (C) Representative images
of co‐overexpression of RFP and PRG3  in  the presence of dominant active RhoAV14. Note  the  increased  filopodia  in PRG3 expressing
neurons (arrows). Scale bar represents 20 µm. (D) Disruption of phosphoinositol‐(4,5)‐bisphosphate (PIP2) in PRG3 expressing neurons.  
Representative  pictures  of  GFP  (control)  and  PRG3  overexpressing  (PRG3)  neurons  expressing  the  RFP  –  PLC1  PH  domain  fusion
constructs  (red) as an  in vivo probe  for  intracellular PIP2  localization. Transfection efficacy  is given  in  the upper  right corner. Bottom,
representative  trans‐cellular pixel  traces of PIP2 values  in GFP  (control) and PRG3 overexpressing  (PRG3) neurons.  In PRG3  cells PIP2
membrane dislocation could be observed (arrows). Scale bar represents 20 µm. (E) Axon spreading assay on myelin‐coated substrates.
Representative images of a spreading assay with GFP and PRG3 overexpressing neurons on control substrate and myelin substrate. Note 










25 µM TRP. Control neurites collapsed to over 80 % 
from their initial length within 5 minutes and displayed 
an overall rounded phenotype. In contrast, PRG3 
neurites retracted by 30 % only and the neuronal cell 
shape was unaffected (Fig. 8 A, B). Thus, our data 
demonstrated that PRG3 attenuates the RhoA signaling 
cascade induced by common neurite growth inhibitors. 
We tested calyculin (100 nM), a general cytoskeletal 
collapse-inducing compound, to exclude that PRG3 
may inhibit overall cell motility (Fig. S5 D). Calyculin 
is a strong serine/thereonine protein phosphatase 













































lymerizing actomyosin and microtubules. Following 
calyculin treatment PRG3 expressing neurons contracted 
to the same extent as control neurons, demonstrating that 
PRG3 expression does not impede general cytoskeletal 
dynamics and microtubule function (Fig. S 5 D). 
 
Increased axonal sprouting in PRG3 transgenic 
animals 
 
Our in vitro experiments identified PRG3 as a potential 
opponent of released myelin after spinal cord injury. 





































and PRG3CTMEM expressing cells compared  to  treatment with Δ21  (control peptide sequence of Nogo‐A without collapse activity).  (G)
Quantification  of  neurite  length  of GFP  expressing  neurons.  Three  independent  experiments were  carried  out  and  differences were
considered  statistically  significant  with  *  p<0.05,  **  p<0.01,  ***p<0.001  (two‐sided  t‐test).  Values  are  given  as  mean  ±  SEM.  (H)
Quantification of neurite  length of PRG3 and PRG3CTMEM expressing neurons. Δ20 had no effect on PRG3 overexpression neurons but
significantly  reduced neurite  length of PRG3CTMEM. Three  independent experiments were carried out and differences were considered
statistically significant with * p<0.05, ** p<0.01, ***p<0.001 (two‐tailed t‐test). Values are given as mean ± SEM. 
Figure 6. PRG3 impedes lysophosphatidic acid (LPA) induced axon collapse. (A) Live time collapse assay with axon collapse
inducing LPA. Representative  time  laps microscopy  image  series of GFP and PRG3 expressing neurons  treated with 0.5 µM LPA.
Transfection efficacy is shown in first image bottom right corner. Scale bar represents 50 µm. (B) Quantification of neurite length of
neurons expressing GFP (control) or PRG3. Note, that GFP expressing neurons show significant higher number of retracted neurites
and  round  cell  bodies  during  the  time  lapse  assay.  Three  independent  experiments  were  carried  out  and  differences  were
considered statistically significant with * p<0.05, ** p<0.01, *** p<0.001 (two‐tailed t‐test). Values are given as mean ± SEM.  
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and found spinal cord motor neurons and their efferent 
axons in ventral roots positive for PRG3 (Fig 9 A, B). 
We further assessed the potential of PRG3 to counteract 
axonal damage after spinal cord injury in vivo. For this 
we performed dorsal T-lesion at TH8 followed by axonal 
BDA tracer injection into the motor cortex in Thy-1.2 
promoter driven (neuronal specific) PRG3-GFP 
transgenic mice (PRG3GFPThy1.2, Fig. 9 C) [34]. Camera 
lucida analysis revealed neuronal sprouting 21 days post-
operation in wild-type littermates and PRG3GFPThy1.2 
transgenic mice (Fig. 9 D, E). Increased axonal fibers 
were found 1 mm and 1.5 – 2.5 mm distal to the center of 
the lesion in PRG3GFPThy1.2 mice compared to controls 
(Fig. 9 G, H). Importantly, no difference was found 
proximal to the lesion in both groups indicating equal 
BDA loading and fiber density proximal of the injury 
side (Fig. 9 F).  
 
Hence, we investigated the functional impact of the 
increased axonal sprouting. Complex motor behavior was 



































dized Schnell-swim-test (SST). The test monitors 
compensatory balancing forelimb movements as a sign of 
impaired hind limb motor function (Schnell et al., 
manuscript in preparation). Initially, both groups showed 
comparable peddle scores in training sessions before the 
spinal injury. Following spinal cord lesion, we found 
significantly improved motor function in PRG3GFPThy1.2 




Our report revealed PRG3 as a strong conductor for 
neurite growth in vitro, in vivo and following spinal cord 
lesion. PRG3 is an integral membrane protein with six 
trans-membrane domains and a carboxyl terminal tail 
located putatively in the cytoplasm. Although the PRG 
family consists of 5 sequentially highly conserved 
members, PRG3 showed the strongest effects on morpho-
logy and induced dramatic morphological changes in 
neuronal cells resulting in a pronounced induction of 




































Figure  7.  PRG3  impedes  non‐hydrolysable  lysophosphatidic  acid  (LPA)  induced  axon  collapse.  (A)
Representative time laps microscopy image series of GFP and PRG3 expressing neurons treated with 0.5 µM nhLPA
(non‐hydrolysable lysophosphatidic acid, which is resistant to any ecto‐phosphatase activity). Transfection efficacy
is  shown  in  first  image bottom  right  corner.  Scale bar  represents 50 µm.  (B) Quantification of neurite  length of
neurons expressing GFP  (control) or PRG3. Note,  that PRG3  expressing neurons  are  also  resistant  to  the nhLPA
collapse  inducing  activity.  Three  independent  experiments  were  carried  out  and  differences  were  considered
statistically significant with * p<0.05, ** p<0.01, *** p<0.001 (two‐tailed t‐test). Values are given as mean ± SEM. 





































PRG3 during neuronal development 
 
We started our investigations with the expression 
analysis of all PRG family members in brain and other 
organs. PRG1 and PRG5 expression was found in 
discrete regions of the adult brain. In contrast, PRG3 
transcripts are strongly regulated in development, with 
high expression levels during early postnatal stages [35]. 
In the spinal cord, PRG3 expression was found in 
postnatal stages but was absent in the adult and aged 
spinal cord. 
 
Interestingly, this time window is characterized by an 
overall high activity of structural neuronal plasticity, 
including enhanced neuronal outgrowth and wiring. It is 
tempting to speculate that PRG3 may play a role in 
these processes, especially when considering the 
challenged morphology induced by PRG3 when 
expressed in neurons. However, this interpretation 





































PRG3 regulates synaptic transmission as reported for  
PRG1 [33] needs to be further investigated. It has been 
reported that PRG1 affects spine density and synaptic  
plasticity in a cell-autonomous fashion via interacting 
with protein phosphatase 2A and subsequent β1-
integrin activation [36]. These data have been found 
by investigating PRG1 deficient mice and further 
investigations will focus on the deletion of the prg3 
gene at the genomic level to open such studies in 
vivo. 
 
Our results show that PRG3 accumulates at the tips of 
neuronal processes, to be located primarily in pre-
synaptic end tips and growth cones of neurons. This 
points PRG3 towards a growth navigator in a neurite-
growth inhibitory environment. Such inhibitory brain 
environments are in fact present from postnatal stages on 
into fully matured adult brains and in aged. Interestingly, 
in the brain PRG3 is distributed in neuronal layers where 
structural plasticity is still taken place [35]. 
Figure  8.  PRG3  impedes  Thrombin‐induced  axon  collapse.  (A)  Representative  time  laps
microscopy image series of GFP and PRG3 expressing neurons treated with 25 µM Thrombin (TRP).
Transfection efficacy  is shown  in  first  image bottom  right corner. Scale bar  represents 50 µm.  (B)























































































































(non‐phosphorylated neurofilament)  in murine spinal cord motor neurons  in the ventral horn (A) and their axons  in
the ventral root (B). Scale: 20 µm. (C) Schematic  illustration of the Thy1.2 driven PRG3GFP transgenic mouse, cDNA
construct of PRG3‐GFP was  subcloned downstream of  the artificial Thy1 neuronal  specific promoter,  the construct







SEM. Statistical differences were analysed by  two way anova with Bonferroni post hoc analysis  including  repeated
measurement correction (n = 5 per group). P value was set as * = p<0.05: ** = p<0.01; *** = p<0.001. 
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PRG3 forms filopodia and elongates neurite growth 
upstream of RasGRF1 
 
When expressed, PRG3 drastically challenges cell 
morphology especially of neuronal cell types. 
Formation of fine and long filopodia and membrane 
protrusions with complex PRG3 positive branching was 
observed. Conversely, RNAi knock down of PRG3 
impeded filopodia formation and neurite outgrowth 
resulted in neurite lengths below the level of controls 
[35]. These membrane protrusions are driven by 
cytoskeletal dynamics, which are to a large extent 
regulated by the small molecular weight GTPases of the 
Rho family [13, 37]. So far, the Rho family GTPase 
Cdc42 occupies a central position in regulating actin 
filament extensions and forming filopodia of different 
length and width [38, 39]. Within Cdc42 signaling 
events, activation of WASP and N-WASP by Cdc42 in 
the presence of PIP2 leads to ARP2/3 activation, which 
acts as a growth promoter for actin filaments, leading to 
the concept of ‘convergent-elongation’ model of 
filopodia formation [14, 40, 41]. However, the 
morphology of PRG3-induced filopodia resembled a 
phenotype also referred to hedgehog-like phenotype, 
which are in stark contrast to the short and thick 
filopodia characteristic for Cdc42 [22, 23]. 
 
Alternatively to Cdc42, Ras - Raf and MEK pathway 
was reported to induce neurite outgrowth [42]. This Ras 
pathway was critical for PRG3 mediated neurite 
formation. PRG3 full-length and PRG3CT induced 
filopodia outgrowth which was effectively reduced 
when the Ras mediator RasGRF1 was silenced. Our 























carboxy terminal domain is essential for operating as 
filopodia forming and growth-promoting. Remarkably, 
filopodia formation was rescued when expressing the 
membrane tagged carboxyl terminus. The function of the 
amino terminal six integral membrane domains needs yet 
to be determined, since plasma membrane targeting of 
the C-terminal domain rescued neurite growth activity. In 
contrast to PRG1, no ecto-enzymatic activity was found 
in the intracellular loops of PRG3 [23, 24]. Thus, the 
integral membrane domains may primarily serve as 
plasma membrane integrator and localizer. The topology 
renders PRG3 as a potential sensor, channel or receptor 
and therefore integral membrane domains are required 
for the exposure of putative extracellular binding 
domains to the outer surface.  
 
We investigated the biochemical basis of the neuronal 
outgrowth phenotype by screening for consensus 
sequences of PRG3 C-terminus and other PRG’s. Only 
two Ca2+ binding domains, CVVXNFKG and 
PXXESPLE were identified, whereas the rest of the 48 
amino acid carboxy tail are disparate and do not give 
clear similarity hits to known protein domains. 
Noteworthy is a recent study reporting the interaction of 
PRG3/LPPR1 with other members of the PRG family 
[43]. Yu and colleagues reported that PRG1 facilitates 
the localization of PRG3 to the membrane and thereby 
promotes filopodia formation. 
 
PRG3 overcomes RhoA mediated neurite growth 
inhibition via PIP2 translocation 
 
Filopodia formation and growth cone shaping are 
























Figure  10.  Scheme  of  the  PRG3  action  on  RhoA‐Rock‐PIP5K  and  RasGRF1  signaling  in  axon
growth and neuronal plasticity. There is experimental evidence for two independent functions of PRG3.
First, PRG3 interferes with the RhoA‐Rock‐PIP5K pathway through translocation of the lipid messenger PIP2.
This  central  signal  interference  affects  general  downstream  neurite  growth  inhibitors  such  as  myelin‐
associated molecules  such  as  Nogo‐A,  LPA  and  Thrombin.  Secondly,  interaction  of  PRG3 with  RasGRF1
induces filopodia formation and neuronal plasticity via downstream effectors such as Raf and MEK.  
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plicated in neuritogenesis [21, 44]. Knock down of 
PRG3 by RNAi impedes this process, pointing to an 
essential role of PRG3 in neurite formation [35]. 
Indeed, PRG3 is mainly localized at the plasma 
membrane and is enriched at the tips of filopodia and 
neurites. PRG3 expression is temporally restricted with 
highest levels in early postnatal stages, emerging in 
parallel to the repellent extracellular space at this 
developmental stage [2, 45]. We therefore asked 
whether PRG3 counteracts the inhibitory signals present 
during development and tested myelin-associated and 
various neurite growth inhibitors. Interestingly, PRG3 
expressing neurites counteracted neurite-collapsing 
activities of myelin. Separate investigations of LPA, 
non-hydrolysable LPA (nhLPA) and thrombin revealed 
resistance to axon collapse and neurite retraction 
independently of the inhibitor used. These data indicate 
that PRG3 modulates a common downstream effector of 
myelin-associated growth inhibitors. Noteworthy, LPA 
receptors, Thrombin receptor and NgR, PirB/LILRB2 
receptor signaling converge to the RhoA-ROCK-PIP5K 
kinase pathway eventually leading to actin depolyme-
rization and neurite collapse [4, 28, 46]. It is tempting to 
speculate that PRG3 interferes at one level in this 
pathway and counteracts further downstream signaling 
in the conditions we used. Indeed, when PIP5K was 
overexpressed to reduce the available PIP2 pool, co-
expression of PRG3 released the available membrane 
bound PIP2 pool resulting in filopodia growth [22].  
 
Thus, these data are consistent with the notion that 
under neurite retracting conditions PRG3 interferes with 
the common RhoA-ROCK-PIP5K pathway and 
counterbalances the axon collapsing activity (Fig. 10). 
Whether this scenario also happens during different 
developmental phases in the brain is a topic of ongoing 
research. So far, we propose that PRG3 promotes 
filopodia initiation and neurite growth during the 
critical periods of CNS (brain and spinal cord) 
development and may assist in events of axonal fine 
tuning finalizing neuronal circuits. Moreover, PRG3 can 
interfere with signals coming from a repelling 
microenvironment, thus making this trans-membrane 
protein a valid candidate for promoting neuronal 
regeneration in the adult.  
 
PRG3 overcomes axonal repulsion in vivo 
 
One urgent quest in a clinical setting is to promote 
spinal cord regeneration after traumatic spinal injury. 
We investigated the potential impact of PRG3 on spinal 
nerve regeneration, using transgenic mice over-
expressing PRG3GFPThy1.2 in neurons of the motor 
cortex. Following dorsal lesion of spinal axons in mice, 
PRG3 transected fibers showed increased sprouting 
distal of the lesion. Importantly, these sprouts are 
crucial for spinal cord regeneration [47, 48]. We 
performed locomotor function tests in PRG3GFPThy1.2 
transgenic animals and control littermates to evaluate 
the functional consequences of increased axonal 
regeneration. We found improved motor function in 
PRG3GFPThy1.2 mice. These data demonstrate that 
PRG3 impedes neuronal growth restriction in vivo and 
fosters functional regeneration in the adult central 
nervous system. 
 
In summary, PRG3 is an integral trans-membrane 
protein and is highly enriched at filopodia and neurite 
tips in vitro and pre- and post-synaptically in vivo. 
PRG3 expression promotes the extension of axons and 
its growth-promoting activity is linked to its carboxyl 
terminus. The plasma membrane localization of the 
PRG3 carboxyl terminus is pivotal for its function. This 
function is executed via a RasGRF1 dependent pathway 
for filopodia formation and axon growth. PRG3 
prevents LPA, TRP and myelin-induced axon collapse 
via PIP2 membrane release.  
 
In a clinically important setting we tested the role of 
PRG3 in spinal cord lesion. We could show that PRG3 
promotes significantly axonal outgrowth and functional 
recovery in vivo after spinal cord injury. Essentially one 
of the challenges in CNS repair and therapy can be 
thought of as ’turning back the clock’: promoting 
processes that occur during development but fail to or 
proceed inefficiently after maturation or injury. Here, 
we provide evidence that PRG3 may represent one 




Cell lines, transfection and immunoblotting 
 
The rodent neuroblastoma cell line N1E-115 was 
obtained from ATCC/LGC-2397 (Germany) and was 
cultured under standard condition containing DMEM 
medium (Biochrom, Berlin, Germany) supplemented 
with 10% fetale bovine serum (Biochrom, Berlin, 
Germany), 1% Penicillin/Streptomycin (Biochrom, 
Berlin, Germany) and 1% Glutamax (Gibco/Invitrogen, 
California, USA). Cells were passaged at approx. 80% 
confluence by adding trypsin after 1 PBS wash step and 
incubated for 5 min, then centrifuged at 900rpm/5 min.) 
Cell lines were transfected according to Broggini et al 
[24]. Briefly, cells were plated at 20 000 /cm² in 6-well 
plates and held under standard conditions. 24h after 
seeding transfection was performed using Roti-Fect 
(Roth, Karlsruhe, Germany) according to the 
manufacturer´s protocol. Western blot analysis was 
performed as described previously [49]. Cells were 
maintained under standard conditions. For protein 
extraction samples were lysed with NP 40 buffer 
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containing a protease inhibitor cocktail (Roche, Basel, 
Switzerland) and homogenized by ultrasound (Bandelin 
Sonoplus, at 67 %). After 20 min on ice, samples were 
centrifuged at 8000 rpm for 8 min. Supernatants were 
measured with Nano-drop (Thermo-scientific, 
Massachusetts, USA). Samples were mixed with 
loading buffer (4x) and Reducing agent (10x) 
(Invitrogen, California, USA) and boiled at 96°C for 8 
min. Equal amounts of protein sample were loaded on 
4-12 % SDS-NuPage Gel (Invitrogen, CA, USA) and 
electrophoresis was performed in MOPS-buffer, 
transferred on PVDF membranes (Roth, Karlsruhe, 
Germany) and efficiency was checked with Memcode 
Stain kit (Thermo Massachusetts, USA) according to 
the user manual. Membranes were blocked in PBS 
containing 2 % Magic block and 10 % Top block 
(Lubio science, Lucern, Switzerland) for 1h before 
further processed. Antibodies were incubated overnight 
at 4°C in roller tubes, followed by secondary 
antibodies incubated at room temperature for 1 hour. 
Detection was performed with ECL plus kit (GE-
healthcare, Solingen, Germany). 
 
Primary cell culture 
 
Primary neuronal cortical cultures were prepared from 
E18 rat embryos and 7 x 104 cells seeded on 12 mm 
glass coverslips coated with poly-L-lysine (0.1 mg/ml 
H2O) and cultured for 48 h in Neurobasal medium 
supplemented with 0.5 % GlutaMax, 0.02% B27 and 1 
% Penicillin/Streptomycin (all from Gibco/Invitrogen). 
After two days of cultivation cells were processed for 
immunostaining essentially as described [50]. Briefly, 
cells were fixed by addition of equal volume of 4 % 
PFA directly into the medium for 15 min at 37°C. 
Afterwards, cells were washed in PBS and post-fixed 
for 20 min in 4 % PFA at room temperature (RT). Cells 
were permeabilized in 0.2 % Triton X-100, blocked 
with 5 % goat serum, 0.1 % BSA in PBS for 1 h and 
incubated with primary antibodies specific to PRG-3 
(D43 clone, dilution 1:5000) and βIII tubulin (Covance, 
dilution 1:1000) were applied overnight at 4°C followed 
by washing steps in PBS and incubation with Alexa 
fluorophore-conjugated secondary antibodies. Images 
were acquired by confocal microscopy with an LSM510 
microscope (Zeiss). 
 
Antibody generation and immunoblots 
 
We designed peptide antibodies against PRG3 based on 
the protein sequence in the hydrophilic domains. The 
following peptide sequences were used: aa position 
280-293 of the C-terminus of human PRG3: 
KGTQGSASKPKPED, aa position 296-310 (D43) of 
the CT of human PRG3: GVPLMAFPRIESPLE; aa 
position 186-199 of the third extracellular loop of 
human PRG3: LEVIEKARRSFPSK; aa position of the 
N-terminal domain of human PRG3: 
MAVEGNNTQRSYSIIP. Peptides were synthesized at 
the core facility of the Netherlands Cancer Institute 
(Henk Hillman, Amsterdam, The Netherlands). An 
amino-terminal cysteinyl residue, which is not part of 
the PRG3 sequence, was included for conjugation of the 
peptide to a carrier protein. Rabbits were immunized 
and the specificity of the serum was further tested on 
immunoblots and on tissue sections by blocking via 
peptide incubation prior to adding the antiserum. PRG3 
antisera were used at a 1:2000 to 1:5000 dilution. 
Secondary anti-rabbit antibody coupled with 
horseradish peroxidase was used at a 1:5000 dilution, 
and visualized by incubation in ECL detection reagents 
(Amersham Pharmacia, Germany), and for equal 
loading controls a mouse β-actin monoclonal antibody 
(Sigma, Germany) was facilitated. 
 
Expression vectors and knock down vector cloning 
 
RT-PCR was used for cloning of PRG3 from rat, mouse 
and human mRNA samples. For sequence alignments 
and homology searches of PRGs we utilized the 
www.ncbi.nlm.nih.gov database and A Plasmid editor 
software (ApE; MW Davis, Utah, USA). Trans-
membrane domains have been predicted using the Kyte 
Doolittle algorithm and all orthologous sequences of 
PRG3 (human, mouse and rat) are deposited at the 
NCBI database (Human PRG3 GenBank accession no. 
AY304516; Rattus norvegicus PRG3 GenBank 
accession no. AY299399; Mus musculus PRG3 
GenBank Accession no. AY345342). We amplified the 
fragments by PCR and cloned the resulting amplicons 
into the pEGFP (Takara, Heidelberg, Germany), and 
pCLEG (Stefan Schumacher, Ulm, Germany) vectors. C-
terminal domain of PRG3 was cloned respectively. 
According to the criteria of Naito et al [51] two short 
interfering RasGRF1 RNAs were designed. Cloning of 
the synthetic oligonucleotides into the pSuperRFP vector 
(modified pS-GFPneo; OligoEngine, Seattle, USA) was 
performed by digesting the empty vector with Bgl2 and 
EcoR1 according to the manufacturer’s instruction.  
 
Immunocytochemistry and histological analysis 
 
Cells were plated 2500/cm² in 12 well plates on 
coverslips and cultured under standard condition for 
several days. Cells were than fixed with 4 % PFA and 
immuno-stained for actin (Thermo scientific, 
Massachusetts, USA) overnight and DAPI (1:10000) for 
additional 5 min. Coverslips were mounted on slides 
with Immu-Mount (Thermo scientific, Massachusetts, 
USA). Pictures were taken with Olympus X71 
microscope with x1000 magnitude. Exposure time was 
equal in different cell lines. Images were taken with 
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cell- F software (Olympus, Tokyo, Japan). Image 
quantification was performed with CellProfiler 2.0 
Software (Broad Institute). Animals were deeply 
anesthetized, followed by PBS and PFA (4%) perfusion. 
The brains were harvested and fixated in PFA o/n and 
dehydrated by a sucrose gradient (10%, 20% and 30%). 
After dehydration, the tissue was emerged in Tissue Tek 
(Sakura, Netherlands) and frozen at -20°C. Cryosections 
(20 µm) were obtained on coverslips and permeabilized 
using methanol. Slices were blocked with 1% Casein 
(Sigma, Germany) for 1 hour.  
 
Spinal cord and ventral root immunostaining 
 
Deeply anesthetized mice were perfused with 4 % PFA, 
and spinal cords with attached ventral roots dissected, 
post-fixed overnight, and cryoprotected in 30 % sucrose 
for 2 – 3 days at 4°C. After tissue embedding, 20 µm 
transverse sections of the spinal cord were cut on a 
cryostat and blocked with PBS containing 0.1 % Triton 
X-100, 5 % goat serum, and 0.5 % BSA, on glass slides. 
Sections were blocked with 5 % goat serum, incubated 
overnight with primary antibodies specific to PRG3 and 
nonphosphorylated neurofilament (SMI32, Covance) 
including 0.5 % BSA, washed, incubated with fluoro-
chrome-conjugated secondary antibodies, and mounted 
in Fluoromount [52]. Images were acquired by confocal 
microscopy with an LSM510 microscope (Zeiss). 
 
Electron microscopy  
 
One 3-month old mouse, deeply anesthetized with a 
mixture of Dormicum and Hypnorm (15 μl/g body 
weight), was transcardially perfused with phosphate-
buffered saline (PBS), followed by 150 ml of a fixative 
containing 4% formaldehyde and 0.05% glutaraldehyde 
in PB (0.1 M, pH 7.4) according to a protocol approved 
by the Veterinary Department of the Canton Zurich. 
Brain was postfixed for 1 h and, after several washes in 
PB, 100-μm-thick vibratome sections were obtained 
from the cerebral cortex and hippocampus. For pre-
embedding immunoperoxidase method, sections were 
incubated in 10% goat serum in PBS for 1 h and 
incubated with 1 μg/ml of the antibody D43 in 2% goat 
serum/PBS for 2 days at 4°C. After several washes in 
PBS the tissue was processed for the avidin-biotin 
horseradish peroxidase complex method (ABC Elite; 
Vector Laboratories, Burlingame, CA, U.S.A.). Sections 
were washed in cacodylate buffer (0.1M) and osmicated 
in 1% OsO4 for 30 min, dehydrated in increasing 
concentrations of ethanol, and embedded in Epon 
resins. Ultrathin sections were imaged using a digital 
camera (Gatan 791 multiscan; Gatan Inc., Pleasanton, 
CA, USA) attached to an EM10C electron microscope 
(Zeiss, Oberkochen, Germany). 
In vitro live cell imaging 
 
Cells were plated on 8 cm2 cell culture dish with a cell 
density of 4000 cell per cm2. Control cells were 
transfected with peGFP-N1. Cells were continuously 
exposed to the light and 38 °C temperature during the 
experiment. Experiments were performed using Zeiss 
Axiovert 20 M (Zeiss, Jena, Germany), camera exposer 
time was set to 500 ms. Movies were acquired with 
Axiovision Software (Zeiss, Jena, Germany). In control 
peGFP-N1 transfected cells no morphological changes 
were found during 1 h . No morphological change was 
visible. 
 
PIP2 distribution in cells  
 
For PIP2 distribution detection was performed as 
described [53]. Briefly cells were plated on coverslips 
and then transfected with a RFP fusion protein 
containing the PH domain of PLC1. This construct 
(RFP-PHPLC) functions as an in vivo probe for 
intracellular localization of PtdIns(4,5)P2. Twenty hours 
after transfection coverslips were mounted and cellular 
distribution of RFP-PHPLC was examined by confocal 
microscopy. Quantification of the membrane- cytosol 
ratio for RFP-PHPLC was performed with Image J.  
 
In utero electroporation 
 
The in utero electroporation experiments were carried 
out as described [54], in accordance with a protocol 
approved by the local animal welfare committee. 
Briefly, we used time-pregnant mice at E15–E16 (post 
coitum). The uterine horns of anesthetized mice were 
exposed and the DNA solution was injected through the 
uterine wall into the lateral ventricle of two of the 
embryos. Five 38 V pulses of 50 ms were applied at 950 
ms intervals by holding the injected brain with forcep-
type electrodes connected to a square–pulse generator 
(CUY 21 Edit, Unique Medical Imada, Miyagi, Japan). 
 
Dorsal hemi section and anatomical analysis 
 
Dorsal hemisection (T-lesion) in mice was performed as 
previously described [31]. Briefly, eight to seventeen 
weeks old PRG3GFPThy1.2 mice and wild-type 
littermates of both sexes (with 20 – 32 g body weight) 
were taken. Anaesthesia was performed with a 
subcutaneous injection of Hypnorm (120 µl / 200 g 
body weight; VetaPharma Limited, Sherburn-in-Elmet, 
UK), and Dormicum (0.75 mg in 150 µl distilled water 
per 200 g body weight; Roche Pharmaceuticals, Basle, 
Switzerland). Vitamin A eye ointment (Vitamin A 
Augensalbe®, Bausch & Lomb Swiss AG, Steinhausen, 
Switzerland) was applied to protect the eyes from 
dehydration during the operation procedure. A partial 
www.aging‐us.com  2480  AGING (Albany NY) 
laminectomy was performed at the thoracic level Th8 
and T-lesion was conducted. Two weeks later, the 
animals were injected with 1.2 μl of a 10% of the high-
resolution, anterograde tracer biotin dextran amine. 10 
days after the tracer injection, animals were sacrificed. 
The spinal cords and brains were dissected and 
histologically processed. On sagittal sections, the 
number of intersections of BDA-labeled fibers with a 
dorsoventral line positioned at defined distances distal 
from the middle of the lesion was counted at a final 
magnification of 400x. The obtained sum of fibers was 
normalized for interindividual tracing variability by 
relating it to the total number of BDA-positive 
corticofugal fibers (determined in six cross-sections of 
the medulla oblongata rostral the pyramidal 
decussation) for each animal. The entire evaluation was 
performed on number-coded, randomly mixed animals, 
i.e., without knowing the genotype of the animals. 
Statistical comparison was done with the unpaired 
Students two tailed t-test if not otherwise stated. 
 
Behavioral testing and Schnell swim test (SST) 
 
Baseline swim measurements were conducted after 
three weeks of handling and training as previously 
described [47]. At this time point most of the animals 
had become used to the swimming task and had stopped 
the occasional use of their forelimbs. After experimental 
spinal cord injury, behaviour was assessed at weekly 
intervals. Swimming behavior was used to study 
differences in motor performance. Two examiners were 
needed: one person to handle the mouse and one person 
for camera operations. The setup for the swim test 
consisted of a rectangular Plexiglas basin with a mirror 
placed at the bottom of the pool to allow simultaneous 
recording of side and bottom view of the animal. Water 
temperature was always set at exactly 23˚C in order to 
keep swimming velocity constant. In weekly sessions, 
swimming was documented until three undistracted, 
unhesitant runs per mouse were obtained for reliable 
quantification. The digital video camera (Panasonic, 
NV-MX500EG, with constant shutter speed at 1/250 
sec. and in sequences of 24 frames per sec.) was 
mounted on a trestle which allowed the filming parallel 
to the moving animal. After completion of the 
swimming sessions, video recordings were analyzed 
under slow motion or manual frame-by-frame option. 
Swimming sequences were transferred to a PC and de-
interlaced using Pinnacle Studio Version 10 (Pinnacle 
Systems, Avid Technology, Inc., California) software 
with resulting in 24 fields/sec. The forelimb strokes 
were quantified in slow motion mode and the peddle 
score was calculated. The peddle score determined the 
total of 60 cm distance. This strategy revealed the 
smoothness of each run. The mean value of three 
undisturbed runs were chosen and the peddle score 
calculated: Score 1, bilateral foreleg strokes over long 
distance; score 1.5, bilateral foreleg strokes with partial 
gaps without bilateral strokes; score 2, single sided 
foreleg strokes over the total distance or at least half 
distance; score 2.5, random single foreleg strokes; score 
3, no foreleg strokes. More details of the Schnell swim 





Quantitative data from experiments were obtained as 
stated in the figure legend. Analysis was performed 
using unpaired two taled  Student’s t test if not 
otherwise stated (Excel, Microsoft, Seattle, WA, USA). 
Data from all experiments were obtained from at least 
three independent experiments. For survival analysis we 
used the GraphPad Prism software (GraphPad Software, 
Inc., LaJolla, USA). The level of significance was set at 
*p < 0.05. Error bars represent ± SD if not otherwise 




The extended protocol of the Schnell swim test will 
appear in a separate publication (Schnell et al., 
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Supplementary  Figure  S1.  Human  PRG1  ‐ 5  amino  acid  sequence  alignment  to  human  LPP1  /  LPP3  and
comparative analysis of PRG1, PRG2 and PRG3  in neuronal cells.  (A) Amino acid  sequence of human PRG1  to 5
(GenBank  Accession  no.  NM_014839.4,  NM_024888.2,  AY304516,  NM_022737.2,  NM_001037317.1)  aligned  to  human





















































































were  stained positive  for  PRG3  in  primary mixed  neuron‐astrocyte  cultures.  In  comparison,  astrocytes 
were negative for PRG3 immunostaining (Scale bar Neuron = 20µm, scale bar astrocyte = 50 µm). 

















































































protrusions  for  quantification  are  shown  in  bottom  row  (arrows).  Scale  bar  represents  10µm.  (B)  Quantification  of  neurite‐like
membrane protrusions  (sprouting  length)  in GFP, PRG3 and PRG3CTMEM expressing P19  cells. Three  independent experiments were
carried out and differences were considered statistically significant with values mean ± SEM  (one way anova, Bonferroni correction,
multiple  groups  comparison;  *  p<0.05,  **  p<0.01,  ***  p<0.001.  (C)  PRG3  and  PRG3CTMEM  induce  hedgehog‐like  morphological
phenotype in HeLa cells. Representative images of GFP transfected cells (GFP), PRG3 overexpressing HeLa cells (PRG3) and membrane
targeted C‐terminus of PRG3 (PRG3CTMEM). Scale bar equals 10 µm. (D) Quantitative analysis of hedgehog‐like extensions in GFP, PRG3,
and  PRG3CTMEM  expressing  HeLa  cells.  Measurements  of  trunk  branches  (close  to  cell  bodies),  non‐trunk  branches  (peripheral
branches)  and  tip  branches  are  given.  Statistical  analysis was  performed with  one way  anova  (Bonferroni  correction  for multiple
comparisons from three independent experiments); * p<0.05, ** p<0.01, *** = p<0.001. Error bars are given as ± SEM of each group. 
 





















Supplementary  Figure  S4.  RasGRF1  siRNA  knockdown
control  and  cell  line  PRG3  expression  profiling.  (A)  Control
RasGRF1  immuno‐pulldown  shows  effective  RasGRF1  knockdown
after  transfection  (B)  mRNA  expression  of  PRG3  in  different  cell
lines, hippocampal tissue (Hi) served as positive control. 
 
Supplementary Figure  S5.  N1E‐115  LPA  receptor  expression  and  Cell
contraction control using calyculin A.  (A) Expression analysis of PRG3, LPP1,
LPP3  and  control  N1E‐115  cells  shows  expression  of  all  4  receptors.  (B)
Representative  time  laps microscopy  image  series out of  three  independent
experiments are shown of 100nM Calyculin A induced cell collapse in GFP and
PRG3 cells after 80 seconds. Scale bar represents 50µm. 
